|

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） Clinical Trials

1 actively recruiting trial

No change since June 2026

Also known as: HAIC

Top Sponsors

  • Zhujiang Hospital1

Indications

  • OPSCC1
  • OSCC1
  • Ivonescimab1
  • HNSCC1
  • Cancer1

Other1 trial

Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.